Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 410
interventional 375
Observational 30
Registry 5

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 209
Drug|Other 33
Biological 20
Biological|Drug 15
Drug|Procedure 10
Drug|Other|Procedure|Radiation 8
Drug|Radiation 8
Biological|Other 7
Other 6
Biological|Drug|Other|Procedure 5
Biological|Drug|Procedure|Radiation 5
Dietary Supplement|Drug 5
Drug|placebo 5
Biological|Drug|Other 4
Drug|Genetic|Other 4
Drug|Other|Procedure 4
Biological|Drug|Other|Procedure|Radiation 3
Biological|Other|Procedure 2
Biological|placebo 2
Device|Drug 2
Dietary Supplement|Other 2
Drug|Procedure|Radiation 2
Other|Procedure 2
Biological|Device|Drug|Procedure|Radiation 1
Biological|Drug|Genetic|Other 1
Biological|Drug|Procedure 1
Biological|Procedure|Radiation 1
Biological|Radiation 1
Device 1
Device|Other 1
Diagnostic Test|Drug|Procedure 1
Drug|Genetic|Procedure|Radiation 1
Drug|placebo|Procedure 1
Genetic 1
Radiation 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 191
China 50
Korea, Republic of 16
Japan 12
United States|Canada 10
France 8
NA 6
United Kingdom 6
United States|Italy 5
Italy 4
Belgium|France 3
United States|Germany|Italy 3
Canada 2
Germany 2
Hong Kong 2
Singapore 2
Taiwan 2
Thailand 2
United States|Germany 2
United States|Italy|Korea, Republic of 2
United States|United Kingdom 2
Austria|Belgium|Czechia|Denmark|Finland|Germany|Netherlands|Norway|Poland|Portugal|Sweden 1
Austria|Belgium|France|Germany|Greece|Italy|Japan|Netherlands|Poland|Spain|Switzerland|United Kingdom 1
Austria|France|Germany|Switzerland 1
Belgium|France|Germany|Italy|Korea, Republic of|Portugal|Singapore|Spain 1
China|Hong Kong|Korea, Republic of|Singapore|Taiwan 1
Denmark|Finland|Norway 1
Denmark|France|Italy|Netherlands|Spain|United Kingdom 1
France|Belgium 1
Germany|Netherlands|United Kingdom 1
Hong Kong|Japan|Korea, Republic of|Taiwan 1
Japan|Korea, Republic of 1
Korea, Republic of|Malaysia|Singapore 1
Norway 1
Spain|Switzerland 1
United States|Argentina|Australia|Belgium|Canada|Finland|France|Germany|Hungary|Italy|Spain|Switzerland 1
United States|Australia 1
United States|Australia|Austria|Belarus|Belgium|Brazil|Bulgaria|Canada|Chile|Czechia|Denmark|Egypt|France|Germany|Hungary|Israel|Italy|Mexico|Netherlands|New Zealand|Peru|Poland|Portugal|Puerto Rico|Romania|Russian Federation|Slovakia|Spain|Sweden|Turkey|United Kingdom 1
United States|Australia|Austria|Belgium|Brazil|France|Germany|Italy|Poland|Spain|Switzerland|United Kingdom 1
United States|Australia|Austria|Canada|Germany|Netherlands|Poland|Russian Federation|Switzerland|United Kingdom 1
United States|Australia|Austria|Canada|Germany|Poland|Russian Federation|Switzerland|United Kingdom 1
United States|Australia|Austria|Finland|France|Germany|Italy|Spain|Switzerland|United Kingdom 1
United States|Australia|Belgium|Canada|France|Italy|Spain|United Kingdom 1
United States|Australia|Canada|Czechia|Denmark|France|Germany|Hungary|Israel|Italy|Korea, Republic of|Poland|Romania|Spain|Taiwan|United Kingdom 1
United States|Australia|Czechia|France|Germany|Poland|Spain|Sweden|Ukraine|United Kingdom 1
United States|Australia|Denmark|France|Germany|Italy|Japan|Netherlands|Spain|Switzerland|United Kingdom 1
United States|Australia|France|Italy|Korea, Republic of|Poland|Russian Federation|Spain|Turkey 1
United States|Australia|Korea, Republic of 1
United States|Australia|Puerto Rico 1
United States|Belgium|Canada|Croatia|Denmark|France|Germany|Hungary|Israel|Italy|Netherlands|Poland|Russian Federation|Slovakia|South Africa|Spain|United Kingdom 1
United States|Belgium|Canada|France|Italy|United Kingdom 1
United States|Belgium|France|Italy|Spain|United Kingdom 1
United States|Canada|China|France|Germany|Hong Kong|Italy|Taiwan 1
United States|China|Japan|Singapore 1
United States|Finland|France|Netherlands|Spain 1
United States|France 1
United States|France|Germany 1
United States|France|Germany|Italy|Spain|United Kingdom 1
United States|France|Germany|Poland|Russian Federation|United Kingdom 1
United States|France|Germany|Portugal|Spain|United Kingdom 1
United States|France|Italy|Netherlands|Spain|Switzerland 1
United States|France|Netherlands|United Kingdom 1
United States|Germany|Sweden|United Kingdom 1
United States|Korea, Republic of|Spain 1

Sites per Study

Site_count Study_Count
1 187
2 23
3 16
4 11
5 24
6 8
7 7
8 6
9 4
10 8
11 11
12 6
13 6
15 3
16 3
17 4
18 1
19 2
20 5
21 5
22 1
23 3
24 1
25 1
27 1
30 1
31 1
32 2
33 1
34 3
35 1
36 1
39 1
40 1
41 2
43 1
44 1
47 1
49 1
59 1
62 1
73 1
77 1
90 1
117 1
131 1
144 1
152 1
161 1

Phase

Phase Study_Count
Phase 2 169
Phase 1 94
Phase 1/Phase 2 55
N/A 20
Phase 3 19
Phase 4 13
Phase 2/Phase 3 3
Early Phase 1 2

Number of Arms

Number_of_Arms Count_of_Studies
1 264
2 56
3 17
4 4
5 1
6 4
7 1
8 2
NA 26

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 8.00 5.0000 2.00000 13.00000 1.00000 9.00000 20.0000 1.00000
1st Qu. 14.25 27.5000 18.00000 28.00000 28.00000 15.00000 105.0000 22.00000
Median 20.50 55.0000 30.00000 42.50000 40.00000 21.00000 169.0000 59.00000
Mean 20.50 115.3158 39.47312 51.98148 55.62424 56.33333 257.3158 64.61538
3rd Qu. 26.75 80.0000 50.00000 60.25000 72.00000 80.00000 267.5000 100.00000
Max. 33.00 713.0000 210.00000 177.00000 250.00000 139.00000 1337.0000 195.00000

Trial Group Type

group_type Group_Count
Experimental 445
Active Comparator 26
NA 26
Other 13
Placebo Comparator 6
No Intervention 4
Sham Comparator 1

Intervention Model

intervention_model Study_Count
Single Group Assignment 294
Parallel Assignment 60
Sequential Assignment 12
NA 6
Crossover Assignment 2
Factorial Assignment 1

Primary Purpose

primary_purpose Study_Count
Treatment 355
Supportive Care 10
Diagnostic 4
Other 2
Prevention 2
Basic Science 1
Screening 1

Observational Studies

Studies by Country

Country Study_Count
United States 14
Korea, Republic of 5
China 3
Japan 2
France 1
Guadeloupe|Martinique 1
Netherlands 1
Spain 1
United States|Argentina|Brazil|Chile|China|France|Israel|Italy|Korea, Republic of|Slovakia|Spain|Switzerland|United Kingdom|Uruguay 1
United States|Australia|Canada|Puerto Rico 1

Sites per Study

Site_count Study_Count
1 20
2 4
3 1
10 2
68 1
76 1
130 1

Enrollment Metrics

Measure Observational
Min 6.00
1st Qu 34.75
Median 115.00
Mean 368.70
3rd Qu 375.00
Max 3000.00

Observation Model

observational_model Study_Count
Cohort 14
Case-Only 6
NA 5
Other 3
Case-Control 1
Ecologic or Community 1

Time Perspective

time_perspective Study_Count
Prospective 18
Retrospective 9
NA 2
Other 1

Registries

Studies by Country

Country Study_Count
Korea, Republic of 1
NA 1
Spain 1
United States 1
United States|Italy|Romania|Ukraine 1

Sites per Study

Site_count Study_Count
1 2
6 1
14 1
36 1

Enrollment Metrics

Measure Registries
Min 300
1st Qu 500
Median 500
Mean 860
3rd Qu 1000
Max 2000

Registry Model

observational_model Study_Count
Cohort 5

Time Perspective

time_perspective Study_Count
Prospective 4
Cross-Sectional 1

Follow-up

target_duration Study_Count
2 Years 2
5 Years 2
10 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT04414969 Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma https://ClinicalTrials.gov/show/NCT04414969 Recruiting Hunan Cancer Hospital 2022-07-01
NCT04217317 CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT04217317 Recruiting Wake Forest University Health Sciences 2022-06-30
NCT03947255 A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma https://ClinicalTrials.gov/show/NCT03947255 Recruiting Seattle Genetics, Inc. 2024-12-31
NCT03552692 Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma https://ClinicalTrials.gov/show/NCT03552692 Active, not recruiting Fondazione Italiana Linfomi ONLUS 2020-08-31
NCT03409432 Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT03409432 Recruiting Ohio State University Comprehensive Cancer Center 2021-04-30
NCT03380026 Mechlorethamine Induced Contact Dermatitis Avoidance Study https://ClinicalTrials.gov/show/NCT03380026 Recruiting Rochester Skin Lymphoma Medical Group, PLLC 2019-12-13
NCT03363555 SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma https://ClinicalTrials.gov/show/NCT03363555 Active, not recruiting Jiangsu HengRui Medicine Co., Ltd. 2019-06-30
NCT03357224 PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL) https://ClinicalTrials.gov/show/NCT03357224 Recruiting European Organisation for Research and Treatment of Cancer - EORTC 2021-09-30
NCT03333486 Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer https://ClinicalTrials.gov/show/NCT03333486 Recruiting Roswell Park Cancer Institute 2022-09-06
NCT03321890 Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) https://ClinicalTrials.gov/show/NCT03321890 Recruiting Sun Yat-sen University 2020-12-01
NCT03292406 A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) https://ClinicalTrials.gov/show/NCT03292406 Active, not recruiting Galderma R&D 2020-09-30
NCT03278782 Study of Pembrolizumab (MK-3475) in Combination With Romidepsin https://ClinicalTrials.gov/show/NCT03278782 Active, not recruiting M.D. Anderson Cancer Center 2020-11-30
NCT03268889 Chidamide With CHOP Regimen for de Novo PTCL Patients (CHOP: Cyclophosphamide, Etoposide, Vincristine and Prednisone; PTCL: Peripheral T Cell Lymphoma) https://ClinicalTrials.gov/show/NCT03268889 Recruiting The First Affiliated Hospital of Soochow University 2020-06-15
NCT03263637 Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies https://ClinicalTrials.gov/show/NCT03263637 Active, not recruiting AstraZeneca 2021-12-31
NCT03259503 Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant https://ClinicalTrials.gov/show/NCT03259503 Recruiting M.D. Anderson Cancer Center 2023-07-01
NCT03246750 B-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell Lymphoma https://ClinicalTrials.gov/show/NCT03246750 Recruiting The Thai Lymphoma Study Group 2021-06-30
NCT03240211 Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL https://ClinicalTrials.gov/show/NCT03240211 Recruiting Columbia University 2019-12-31
NCT03228836 Efficacy and Safety Evaluation of IBI308 in Patients With Extranodal NK/T Cell Lymphoma Patients https://ClinicalTrials.gov/show/NCT03228836 Active, not recruiting Innovent Biologics (Suzhou) Co. Ltd. 2018-02-07
NCT03218683 Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies. https://ClinicalTrials.gov/show/NCT03218683 Active, not recruiting AstraZeneca 2022-01-11
NCT03217643 CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1. https://ClinicalTrials.gov/show/NCT03217643 Recruiting Imagine Institute 2021-09-30
NCT03212937 Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT03212937 Active, not recruiting National Cancer Centre, Singapore 2020-02-29
NCT03210662 Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03210662 Recruiting M.D. Anderson Cancer Center 2020-11-30
NCT03192202 AFM13 in Relapsed/Refractory Cutaneous Lymphomas https://ClinicalTrials.gov/show/NCT03192202 Recruiting Columbia University 2020-08-31
NCT03161223 Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma https://ClinicalTrials.gov/show/NCT03161223 Recruiting Columbia University 2021-02-28
NCT03154918 GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell Lymphoma https://ClinicalTrials.gov/show/NCT03154918 Recruiting Sichuan University 2020-12-31
NCT03154710 Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High Risk of Relapse in Complete or Partial Response https://ClinicalTrials.gov/show/NCT03154710 Recruiting Weprom 2022-01-31
NCT03150602 A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy https://ClinicalTrials.gov/show/NCT03150602 Recruiting Taiwan Mundipharma Pharmaceuticals Ltd. 2020-12-31
NCT03141203 Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients https://ClinicalTrials.gov/show/NCT03141203 Active, not recruiting University of Birmingham 2020-08-31
NCT03116659 CTCL Directed Therapy https://ClinicalTrials.gov/show/NCT03116659 Recruiting James J. Peters Veterans Affairs Medical Center 2020-12-30
NCT03113500 Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT03113500 Recruiting City of Hope Medical Center 2021-01-21
NCT03109353 Modification of Extracorporeal Photopheresis in Cutaneous T-cell Lymphoma or Chronic Graft-versus-host Disease https://ClinicalTrials.gov/show/NCT03109353 Active, not recruiting St. Olavs Hospital 2020-09-30
NCT03071822 Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas https://ClinicalTrials.gov/show/NCT03071822 Recruiting The University of Hong Kong 2021-07-31
NCT03052933 Copanlisib and Gemcitabine in Relapsed/Refractory PTCL https://ClinicalTrials.gov/show/NCT03052933 Active, not recruiting Chonnam National University Hospital 2021-12-31
NCT03046953 Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT03046953 Recruiting University of Birmingham 2020-08-31
NCT03035331 Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03035331 Recruiting Mayo Clinic 2021-02-15
NCT03017820 VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma https://ClinicalTrials.gov/show/NCT03017820 Recruiting Mayo Clinic 2021-01-15
NCT03011814 Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma https://ClinicalTrials.gov/show/NCT03011814 Recruiting City of Hope Medical Center 2023-03-08
NCT02987244 Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT02987244 Recruiting Peking Union Medical College Hospital 2020-03-31
NCT02978625 Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers https://ClinicalTrials.gov/show/NCT02978625 Recruiting National Cancer Institute (NCI) 2021-06-01
NCT02955589 Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL) https://ClinicalTrials.gov/show/NCT02955589 Active, not recruiting HUYA Bioscience International 2018-12-31
NCT02953652 Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) https://ClinicalTrials.gov/show/NCT02953652 Active, not recruiting HUYA Bioscience International 2019-04-30
NCT02927925 A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type https://ClinicalTrials.gov/show/NCT02927925 Completed Janssen Research & Development, LLC 2020-01-02
NCT02879526 Chidamide Combined With Cyclophosphamide, Prednisone, Thalidomide in Treatment of Fragile Patients With Relapse/Refratory Peripheral T Cell Lymphoma https://ClinicalTrials.gov/show/NCT02879526 Recruiting The First Affiliated Hospital with Nanjing Medical University 2019-06-30
NCT02859402 Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas https://ClinicalTrials.gov/show/NCT02859402 Recruiting Keimyung University Dongsan Medical Center 2019-12-31
NCT02825147 Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell Lymphoma https://ClinicalTrials.gov/show/NCT02825147 Completed Ruijin Hospital 2016-03-31
NCT02809573 Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients https://ClinicalTrials.gov/show/NCT02809573 Completed Chipscreen Biosciences, Ltd. 2019-01-08
NCT02797470 Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant https://ClinicalTrials.gov/show/NCT02797470 Recruiting AIDS Malignancy Consortium 2021-09-30
NCT02783625 Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas https://ClinicalTrials.gov/show/NCT02783625 Recruiting Memorial Sloan Kettering Cancer Center 2021-05-31
NCT02764281 MEDA Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Stage IV Natural Killer/T-cell Lymphoma https://ClinicalTrials.gov/show/NCT02764281 Completed Xinhua Hospital, Shanghai Jiao Tong University School of Medicine 2020-02-29
NCT02689453 Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) https://ClinicalTrials.gov/show/NCT02689453 Recruiting National Institutes of Health Clinical Center (CC) 2023-01-31
NCT02676778 Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma https://ClinicalTrials.gov/show/NCT02676778 Completed Eisai Inc. 2019-04-24
NCT02653976 A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) https://ClinicalTrials.gov/show/NCT02653976 Active, not recruiting Solasia Pharma K.K. 2019-12-31
NCT02652715 Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02652715 Completed Mayo Clinic 2018-12-21
NCT02633020 Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease https://ClinicalTrials.gov/show/NCT02633020 Completed Amgen 2017-04-11
NCT02631239 MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma https://ClinicalTrials.gov/show/NCT02631239 Recruiting Ruijin Hospital 2020-11-30
NCT02616965 A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma https://ClinicalTrials.gov/show/NCT02616965 Recruiting Fox Chase Cancer Center 2021-12-31
NCT02594267 A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL) https://ClinicalTrials.gov/show/NCT02594267 Active, not recruiting Acrotech Biopharma LLC 2020-08-31
NCT02593045 Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL) https://ClinicalTrials.gov/show/NCT02593045 Active, not recruiting Innate Pharma 2019-12-31
NCT02588651 A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) https://ClinicalTrials.gov/show/NCT02588651 Recruiting Case Comprehensive Cancer Center 2020-08-31
NCT02576496 Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02576496 Recruiting Mundipharma-EDO GmbH 2021-03-31
NCT01716806 A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) https://ClinicalTrials.gov/show/NCT01716806 Recruiting Seattle Genetics, Inc. 2021-09-30
NCT02567656 Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma https://ClinicalTrials.gov/show/NCT02567656 Completed Rhizen Pharmaceuticals SA 2018-03-31
NCT02561273 Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT02561273 Active, not recruiting University of Nebraska 2020-10-31
NCT02560441 Trial of IPGDP Regimen Chemotherapy in Patients With Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type https://ClinicalTrials.gov/show/NCT02560441 Recruiting Chinese Academy of Medical Sciences 2022-09-30
NCT02546440 Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL) https://ClinicalTrials.gov/show/NCT02546440 Recruiting Universitätsmedizin Mannheim 2020-09-30
NCT02542124 NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT) https://ClinicalTrials.gov/show/NCT02542124 Active, not recruiting Neumedicines Inc. 2019-02-28
NCT02535247 Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02535247 Recruiting Fox Chase Cancer Center 2020-12-31
NCT02533700 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL https://ClinicalTrials.gov/show/NCT02533700 Active, not recruiting Shandong Provincial Hospital 2019-05-31
NCT02520791 Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma https://ClinicalTrials.gov/show/NCT02520791 Recruiting National Cancer Institute (NCI) 2020-12-31
NCT02512497 Romidepsin Maintenance After Allogeneic Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT02512497 Recruiting Ohio State University Comprehensive Cancer Center 2020-12-31
NCT02495415 Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas https://ClinicalTrials.gov/show/NCT02495415 Recruiting CerRx, Inc. 2021-07-31
NCT02464228 Investigation of Tipifarnib in Treatment of Subjects With PTCL That Have Not Responded to Standard Therapy. https://ClinicalTrials.gov/show/NCT02464228 Active, not recruiting Kura Oncology, Inc. 2021-01-15
NCT02448381 FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) https://ClinicalTrials.gov/show/NCT02448381 Active, not recruiting Soligenix 2019-12-31
NCT02445404 Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL https://ClinicalTrials.gov/show/NCT02445404 Recruiting Samsung Medical Center 2020-06-30
NCT02432235 Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02432235 Completed ADC Therapeutics S.A. 2019-10-24
NCT02424968 CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma https://ClinicalTrials.gov/show/NCT02424968 Active, not recruiting Stanford University 2020-07-31
NCT02424045 Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT02424045 Completed Samsung Medical Center 2017-09-30
NCT02362997 Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL https://ClinicalTrials.gov/show/NCT02362997 Recruiting Dana-Farber Cancer Institute 2020-09-30
NCT02342782 Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02342782 Active, not recruiting City of Hope Medical Center 2020-12-31
NCT02341209 Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT02341209 Recruiting Rochester General Hospital 2020-02-06
NCT02309580 Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma https://ClinicalTrials.gov/show/NCT02309580 Recruiting Memorial Sloan Kettering Cancer Center 2020-12-31
NCT02276248 Radiotherapy Combined With GDP Chemotherapy in Stage I/II Extranodal Natural Killer/T-cell Lymphoma https://ClinicalTrials.gov/show/NCT02276248 Completed Chinese Academy of Medical Sciences 2016-12-31
NCT02273739 Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation https://ClinicalTrials.gov/show/NCT02273739 Completed Celgene 2016-06-30
NCT02232516 Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT02232516 Recruiting Northwestern University 2022-07-31
NCT02223208 Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas https://ClinicalTrials.gov/show/NCT02223208 Recruiting Fondazione Italiana Linfomi ONLUS 2021-09-30
NCT02192021 Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL) https://ClinicalTrials.gov/show/NCT02192021 Recruiting University of Pittsburgh 2021-12-31
NCT03385226 A Trial Assessing the Effect of Pembrolizumab Combined With Radiotherapy in Patients With Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS) https://ClinicalTrials.gov/show/NCT03385226 Recruiting University College, London 2022-01-31
NCT02181218 Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas https://ClinicalTrials.gov/show/NCT02181218 Active, not recruiting Washington University School of Medicine 2019-03-28
NCT02168140 CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02168140 Active, not recruiting Wake Forest University Health Sciences 2019-04-18
NCT02158975 Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas https://ClinicalTrials.gov/show/NCT02158975 Completed University of Michigan Rogel Cancer Center 2016-10-31
NCT02106650 Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT02106650 Completed Acrotech Biopharma LLC 2018-10-31
NCT02085655 PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma https://ClinicalTrials.gov/show/NCT02085655 Active, not recruiting Sun Yat-sen University 2018-12-31
NCT01309789 A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms https://ClinicalTrials.gov/show/NCT01309789 Completed Seattle Genetics, Inc. 2013-04-30
NCT01280526 A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas https://ClinicalTrials.gov/show/NCT01280526 Completed The Lymphoma Academic Research Organisation 2012-11-30
NCT01273766 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01273766 Completed Wake Forest University Health Sciences 2012-03-31
NCT03770000 Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma https://ClinicalTrials.gov/show/NCT03770000 Recruiting Rhizen Pharmaceuticals SA 2020-08-31
NCT02811783 Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL https://ClinicalTrials.gov/show/NCT02811783 Recruiting Elorac, Inc. 2022-06-30
NCT02013362 Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT02013362 Completed Mundipharma K.K. 2015-12-31
NCT01991158 GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell Lymphoma https://ClinicalTrials.gov/show/NCT01991158 Active, not recruiting Sun Yat-sen University 2016-12-31
NCT01959477 Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01959477 Completed Case Comprehensive Cancer Center 2015-01-31
NCT01921790 Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma https://ClinicalTrials.gov/show/NCT01921790 Recruiting Sun Yat-sen University 2015-08-31
NCT01921387 Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT01921387 Active, not recruiting Fred Hutchinson Cancer Research Center 2017-07-26
NCT01919619 Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT01919619 Recruiting M.D. Anderson Cancer Center 2021-06-30
NCT01908777 A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01908777 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-07-31
NCT01902225 Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma https://ClinicalTrials.gov/show/NCT01902225 Completed University of California, San Francisco 2018-07-13
NCT01897012 Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas https://ClinicalTrials.gov/show/NCT01897012 Completed National Cancer Institute (NCI) 2018-10-31
NCT01871727 A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01871727 Recruiting Eisai Inc. 2021-03-31
NCT01871675 Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01871675 Completed SCRI Development Innovations, LLC 2016-06-30
NCT01839916 Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01839916 Completed University of Chicago 2018-08-31
NCT01839097 Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL) https://ClinicalTrials.gov/show/NCT01839097 Completed Acrotech Biopharma LLC 2016-01-31
NCT01822886 Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients https://ClinicalTrials.gov/show/NCT01822886 Completed Fondazione Italiana Linfomi ONLUS 2014-12-31
NCT01806337 CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma https://ClinicalTrials.gov/show/NCT01806337 Completed University of Göttingen 2006-07-31
NCT01805037 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas https://ClinicalTrials.gov/show/NCT01805037 Active, not recruiting Northwestern University 2021-01-31
NCT01804335 CD5789 in Early Cutaneous T-Cell Lymphoma (CTCL) https://ClinicalTrials.gov/show/NCT01804335 Completed M.D. Anderson Cancer Center 2015-03-31
NCT01804166 A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn’s Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) https://ClinicalTrials.gov/show/NCT01804166 Completed Janssen Scientific Affairs, LLC 2020-02-29
NCT01800838 Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01800838 Completed Case Comprehensive Cancer Center 2014-09-30
NCT01796002 Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01796002 Active, not recruiting The Lymphoma Academic Research Organisation 2020-03-20
NCT01787409 Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency https://ClinicalTrials.gov/show/NCT01787409 Recruiting Mayo Clinic 2020-11-30
NCT01777152 ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas https://ClinicalTrials.gov/show/NCT01777152 Active, not recruiting Seattle Genetics, Inc. 2018-08-15
NCT01776411 Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients https://ClinicalTrials.gov/show/NCT01776411 Completed Mundipharma K.K. 2016-03-31
NCT01760655 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01760655 Recruiting Thomas Jefferson University 2021-03-31
NCT01748721 MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT01748721 Completed Morphotek 2015-05-31
NCT01728805 Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL https://ClinicalTrials.gov/show/NCT01728805 Active, not recruiting Kyowa Kirin Pharmaceutical Development, Inc. 2017-03-31
NCT01719835 CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study https://ClinicalTrials.gov/show/NCT01719835 Active, not recruiting Royal Marsden NHS Foundation Trust 2016-11-30
NCT01689220 A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea https://ClinicalTrials.gov/show/NCT01689220 Completed Solasia Pharma K.K. 2014-01-31
NCT01679860 Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma https://ClinicalTrials.gov/show/NCT01679860 Completed Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 2011-12-31
NCT01678443 Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT01678443 Active, not recruiting Fred Hutchinson Cancer Research Center 2011-04-11
NCT01676831 Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL) https://ClinicalTrials.gov/show/NCT01676831 Completed Abramson Cancer Center of the University of Pennsylvania 2015-01-31
NCT01664975 Treatment of Peripheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT01664975 Completed Zhengzhou University 2016-04-30
NCT01644253 Phase 1b Safety and Efficacy Study of TRU-016 https://ClinicalTrials.gov/show/NCT01644253 Active, not recruiting Aptevo Therapeutics 2020-10-31
NCT01638533 Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction https://ClinicalTrials.gov/show/NCT01638533 Active, not recruiting National Cancer Institute (NCI) 2018-11-29
NCT01611142 Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL) https://ClinicalTrials.gov/show/NCT01611142 Completed Kyowa Kirin Pharmaceutical Development, Inc. 2015-05-31
NCT01590732 Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01590732 Completed M.D. Anderson Cancer Center 2018-05-02
NCT01588015 Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01588015 Active, not recruiting City of Hope Medical Center 2021-11-30
NCT03349333 A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL https://ClinicalTrials.gov/show/NCT03349333 Completed Mundipharma (China) Pharmaceutical Co. Ltd 2017-07-21
NCT01578499 A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician’s Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) https://ClinicalTrials.gov/show/NCT01578499 Completed Takeda 2016-05-31
NCT01569724 Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma https://ClinicalTrials.gov/show/NCT01569724 Completed Rennes University Hospital 2016-12-31
NCT01567709 Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01567709 Completed National Cancer Institute (NCI) 2018-03-29
NCT01561833 A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients https://ClinicalTrials.gov/show/NCT01561833 Completed Yale University 2013-05-31
NCT01529827 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01529827 Completed Roswell Park Cancer Institute 2015-05-28
NCT01523223 Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies https://ClinicalTrials.gov/show/NCT01523223 Completed Stanford University 2016-09-30
NCT01486277 A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma https://ClinicalTrials.gov/show/NCT01486277 Completed Janssen Research & Development, LLC 2014-11-30
NCT01484015 Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia https://ClinicalTrials.gov/show/NCT01484015 Completed Wake Forest University Health Sciences 2012-06-30
NCT01482962 Alisertib (MLN8237) or Investigator’s Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01482962 Completed Takeda 2015-06-30
NCT01466881 Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01466881 Completed National Cancer Institute (NCI) 2014-12-31
NCT01456039 A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL) https://ClinicalTrials.gov/show/NCT01456039 Completed Celgene 2015-07-28
NCT01445535 Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas https://ClinicalTrials.gov/show/NCT01445535 Active, not recruiting National Institutes of Health Clinical Center (CC) 2011-04-01
NCT01435863 A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) https://ClinicalTrials.gov/show/NCT01435863 Completed Solasia Pharma K.K. 2015-04-30
NCT01433731 Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL) https://ClinicalTrials.gov/show/NCT01433731 Completed TetraLogic Pharmaceuticals 2013-09-30
NCT01431209 Ruxolitinib Phosphate in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01431209 Active, not recruiting University of Nebraska 2021-03-31
NCT01427881 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01427881 Completed Fred Hutchinson Cancer Research Center 2014-06-30
NCT01421667 A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01421667 Completed Seattle Genetics, Inc. 2015-06-30
NCT01403415 Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01403415 Completed National Cancer Institute (NCI) 2015-05-31
NCT01401530 E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01401530 Completed Eisai Inc. 2015-08-31
NCT01384513 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01384513 Recruiting Thomas Jefferson University 2020-12-31
NCT01336933 Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01336933 Completed University of Nebraska 2016-12-28
NCT01336920 Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01336920 Completed University of Nebraska 2015-04-30
NCT01326702 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors https://ClinicalTrials.gov/show/NCT01326702 Completed National Cancer Institute (NCI) 2015-04-30
NCT04444141 A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT04444141 Recruiting Akeso 2021-06-30
NCT04405375 GPED Regimen for Relapsed/Refractory or Advanced ENKTCL https://ClinicalTrials.gov/show/NCT04405375 Recruiting Beijing Tongren Hospital 2023-04-30
NCT04366128 Camrelizumab, Pegaspargase and Apatinib With Radiation Therapy for Stage IE/IIE ENKTL https://ClinicalTrials.gov/show/NCT04366128 Recruiting Xinhua Hospital, Shanghai Jiao Tong University School of Medicine 2021-12-30
NCT04365036 A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy With or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL) https://ClinicalTrials.gov/show/NCT04365036 Recruiting Sun Yat-sen University 2025-04-30
NCT04362007 A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma https://ClinicalTrials.gov/show/NCT04362007 Recruiting Otsuka Pharmaceutical Co., Ltd. 2024-09-30
NCT04334174 Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas https://ClinicalTrials.gov/show/NCT04334174 Recruiting University of Kansas Medical Center 2023-04-30
NCT04329130 Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT04329130 Recruiting Sun Yat-sen University 2022-03-26
NCT04296786 Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study https://ClinicalTrials.gov/show/NCT04296786 Recruiting Peking Union Medical College Hospital 2022-12-31
NCT04279379 Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma https://ClinicalTrials.gov/show/NCT04279379 Recruiting Beijing Tongren Hospital 2022-12-31
NCT04231370 Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell Lymphoma https://ClinicalTrials.gov/show/NCT04231370 Recruiting Beijing Tongren Hospital 2022-02-28
NCT04230330 Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma https://ClinicalTrials.gov/show/NCT04230330 Recruiting National Cancer Centre, Singapore 2022-01-31
NCT04219319 LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma https://ClinicalTrials.gov/show/NCT04219319 Recruiting The First Affiliated Hospital with Nanjing Medical University 2022-11-29
NCT03372057 A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL) https://ClinicalTrials.gov/show/NCT03372057 Recruiting Verastem, Inc. 2021-11-30
NCT04171791 A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL) https://ClinicalTrials.gov/show/NCT04171791 Recruiting Yale University 2021-02-28
NCT04127227 Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type https://ClinicalTrials.gov/show/NCT04127227 Recruiting Sun Yat-sen University 2023-10-09
NCT04121507 ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy https://ClinicalTrials.gov/show/NCT04121507 Recruiting GWT-TUD GmbH 2020-03-30
NCT04105010 Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8) https://ClinicalTrials.gov/show/NCT04105010 Recruiting Dizal (Jiangsu) Pharmaceutical Co., Ltd. 2020-12-31
NCT04101331 Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides https://ClinicalTrials.gov/show/NCT04101331 Recruiting Affimed GmbH 2022-04-30
NCT04096690 Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell Lymphoma https://ClinicalTrials.gov/show/NCT04096690 Recruiting Ruijin Hospital 2021-12-31
NCT04083495 CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma https://ClinicalTrials.gov/show/NCT04083495 Recruiting UNC Lineberger Comprehensive Cancer Center 2021-09-30
NCT04061772 A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma https://ClinicalTrials.gov/show/NCT04061772 Recruiting Zhejiang Cancer Hospital 2021-07-05
NCT04045470 A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT04045470 Recruiting Dana-Farber Cancer Institute 2023-01-01
NCT04040491 PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT04040491 Recruiting Zhengzhou University 2020-12-01
NCT04038411 PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma https://ClinicalTrials.gov/show/NCT04038411 Recruiting Zhengzhou University 2021-04-01
NCT04008394 Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies https://ClinicalTrials.gov/show/NCT04008394 Recruiting Wuhan Union Hospital, China 2022-07-01
NCT04004637 CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT04004637 Recruiting PersonGen BioTherapeutics (Suzhou) Co., Ltd. 2021-06-01
NCT04004572 Sintilimab, Pegaspargase and Anlotinib for Stage IV Natural Killer /T-cell Lymphoma https://ClinicalTrials.gov/show/NCT04004572 Recruiting Xinhua Hospital, Shanghai Jiao Tong University School of Medicine 2020-12-30
NCT03952572 Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT03952572 Recruiting Peking University 2023-04-30
NCT03952078 A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT03952078 Recruiting Corvus Pharmaceuticals, Inc. 2020-12-31
NCT03936452 Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma https://ClinicalTrials.gov/show/NCT03936452 Recruiting Sun Yat-sen University 2020-04-30
NCT03927105 Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma https://ClinicalTrials.gov/show/NCT03927105 Active, not recruiting Big Ten Cancer Research Consortium 2024-05-31
NCT03922724 Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma https://ClinicalTrials.gov/show/NCT03922724 Recruiting National Institutes of Health Clinical Center (CC) 2023-05-27
NCT03921879 Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma https://ClinicalTrials.gov/show/NCT03921879 Recruiting Oncotartis, Inc. 2021-04-30
NCT03905135 Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies https://ClinicalTrials.gov/show/NCT03905135 Recruiting National Institutes of Health Clinical Center (CC) 2022-03-01
NCT03902184 IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma https://ClinicalTrials.gov/show/NCT03902184 Recruiting Innate Pharma 2022-03-01
NCT03853044 Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma https://ClinicalTrials.gov/show/NCT03853044 Recruiting Ruijin Hospital 2020-12-31
NCT03837457 PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who Have Completed the SOLAR Study https://ClinicalTrials.gov/show/NCT03837457 Enrolling by invitation miRagen Therapeutics, Inc. 2021-12-31
NCT03833180 A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies https://ClinicalTrials.gov/show/NCT03833180 Recruiting VelosBio Inc. 2021-03-31
NCT03789617 Clinical Trial to Evaluate the Efficacy and Safety of Epstein-Barr Virus Induced Natural T Lymphocyte(EBViNT) Cell in Patients With Progressive EBV Positive Extranodal NK/T-cell Lymphoma Where Standard Treatments Have Failed https://ClinicalTrials.gov/show/NCT03789617 Recruiting Eutilex 2020-09-30
NCT03775525 Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT03775525 Recruiting Genzada Pharmaceuticals USA, Inc. 2020-09-30
NCT03730740 Phase II of Lenalidomide After Salvage Therapy in R/R Non-Hodgkin T-cell Lymphoma https://ClinicalTrials.gov/show/NCT03730740 Recruiting Samsung Medical Center 2021-11-15
NCT03728972 Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type https://ClinicalTrials.gov/show/NCT03728972 Recruiting Memorial Sloan Kettering Cancer Center 2021-11-30
NCT03713320 SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides https://ClinicalTrials.gov/show/NCT03713320 Active, not recruiting miRagen Therapeutics, Inc. 2021-04-30
NCT03703375 Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator’s Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma https://ClinicalTrials.gov/show/NCT03703375 Recruiting Celgene 2021-12-31
NCT03671850 VT-EBV-N for Treatment of Severe in EBV Positive Extranodal NK/T Cell Lymphoma Patients https://ClinicalTrials.gov/show/NCT03671850 Recruiting ViGenCell Inc. 2023-12-04
NCT03631862 Treatment of Newly Diagnosed Peripheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT03631862 Recruiting Zhengzhou University 2019-12-31
NCT03630731 Maintenance Treatment of Chidamide in Stage IV or Relapsed/Refractory Extranodal NK/T-cell Lymphoma https://ClinicalTrials.gov/show/NCT03630731 Recruiting Chinese Academy of Medical Sciences 2020-03-31
NCT03623087 SIMPLE Chemotherapy for NK Lymphoma/Leukaemia https://ClinicalTrials.gov/show/NCT03623087 Recruiting The University of Hong Kong 2020-03-14
NCT03618238 Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma https://ClinicalTrials.gov/show/NCT03618238 Recruiting Xinhua Hospital, Shanghai Jiao Tong University School of Medicine 2020-12-31
NCT03617432 Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients https://ClinicalTrials.gov/show/NCT03617432 Recruiting Peking University 2020-09-30
NCT03602157 Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL https://ClinicalTrials.gov/show/NCT03602157 Recruiting UNC Lineberger Comprehensive Cancer Center 2026-09-30
NCT03601819 Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders https://ClinicalTrials.gov/show/NCT03601819 Recruiting University of Michigan Rogel Cancer Center 2021-09-30
NCT03598998 Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas https://ClinicalTrials.gov/show/NCT03598998 Recruiting City of Hope Medical Center 2021-04-27
NCT03593018 Efficacy and Safety of Oral Azacitidine Compared to Investigator’s Choice Therapy in Patients With Relapsed or Refractory AITL https://ClinicalTrials.gov/show/NCT03593018 Recruiting The Lymphoma Academic Research Organisation 2021-12-31
NCT03590574 Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma https://ClinicalTrials.gov/show/NCT03590574 Recruiting Autolus Limited 2021-07-31
NCT03586999 Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas https://ClinicalTrials.gov/show/NCT03586999 Recruiting University of Colorado, Denver 2020-08-31
NCT03586024 Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas https://ClinicalTrials.gov/show/NCT03586024 Active, not recruiting Abramson Cancer Center of the University of Pennsylvania 2022-03-12
NCT03547700 Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL) https://ClinicalTrials.gov/show/NCT03547700 Recruiting Big Ten Cancer Research Consortium 2020-07-31
NCT03542266 CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT03542266 Active, not recruiting Weill Medical College of Cornell University 2020-03-25
NCT03534180 Venetoclax in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT03534180 Recruiting City of Hope Medical Center 2020-08-21
NCT03502629 Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226) https://ClinicalTrials.gov/show/NCT03502629 Recruiting Genor Biopharma Co., Ltd. 2020-08-31
NCT03501576 Evaluation of Human Immune Responses to Influenza Virus Vaccination in Patients With Lymphoma https://ClinicalTrials.gov/show/NCT03501576 Recruiting Emory University 2021-04-30
NCT03496779 Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine https://ClinicalTrials.gov/show/NCT03496779 Recruiting The Lymphoma Academic Research Organisation 2020-03-31
NCT03493451 Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK- Neoplasms https://ClinicalTrials.gov/show/NCT03493451 Active, not recruiting BeiGene 2021-02-28
NCT03487133 Bortezomib/Dexamethasone Therapy in Patients With Relapsed and/or Refractory Cutaneous T-cell Lymphoma https://ClinicalTrials.gov/show/NCT03487133 Recruiting Samsung Medical Center 2020-12-31
NCT03439501 Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY] https://ClinicalTrials.gov/show/NCT03439501 Active, not recruiting Samsung Medical Center 2021-04-24
NCT01261247 Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01261247 Active, not recruiting Mayo Clinic 2016-05-09
NCT01258998 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma https://ClinicalTrials.gov/show/NCT01258998 Completed National Cancer Institute (NCI) 2014-07-31
NCT01254578 Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers https://ClinicalTrials.gov/show/NCT01254578 Completed National Cancer Institute (NCI) 2012-11-09
NCT01238159 Concomitant Chemo-radiotherapy Followed by MIDLE Chemotherapy in Stage I/II Extranodal NK/T-cell Lymphoma https://ClinicalTrials.gov/show/NCT01238159 Completed Samsung Medical Center 2014-12-31
NCT01233921 Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT01233921 Completed Fred Hutchinson Cancer Research Center 2012-07-31
NCT01226472 Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001 https://ClinicalTrials.gov/show/NCT01226472 Completed Kyowa Kirin Pharmaceutical Development, Inc. 2012-09-30
NCT01198665 RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas https://ClinicalTrials.gov/show/NCT01198665 Completed Samsung Medical Center 2014-12-31
NCT01177371 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01177371 Completed Case Comprehensive Cancer Center 2000-02-29
NCT01169298 A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT01169298 Completed Celgene 2013-12-01
NCT01158274 RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors https://ClinicalTrials.gov/show/NCT01158274 Completed National Cancer Institute (NCI) 2012-08-31
NCT01155817 Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease https://ClinicalTrials.gov/show/NCT01155817 Completed Stanford University 2013-12-31
NCT01134341 Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma https://ClinicalTrials.gov/show/NCT01134341 Completed Acrotech Biopharma LLC 2015-08-31
NCT01129193 AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma https://ClinicalTrials.gov/show/NCT01129193 Completed Ohio State University Comprehensive Cancer Center 2017-01-07
NCT01129180 Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01129180 Completed Ohio State University Comprehensive Cancer Center 2012-05-31
NCT01110135 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma https://ClinicalTrials.gov/show/NCT01110135 Completed University of Washington 2013-11-30
NCT01093586 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01093586 Completed Case Comprehensive Cancer Center 2015-12-31
NCT01076543 Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01076543 Completed National Cancer Institute (NCI) 2017-12-31
NCT01075321 Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01075321 Active, not recruiting Mayo Clinic 2015-02-28
NCT01053494 Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer https://ClinicalTrials.gov/show/NCT01053494 Completed Wake Forest University Health Sciences 2012-02-29
NCT01007526 Concomitant Chemo-radiotherapy Plus VIDL Chemotherapy in NK/T-cell Lymphoma https://ClinicalTrials.gov/show/NCT01007526 Completed Samsung Medical Center 2012-12-31
NCT01007448 Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL) https://ClinicalTrials.gov/show/NCT01007448 Completed Bausch Health Americas, Inc. 2014-02-20
NCT00992446 Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00992446 Completed Fred Hutchinson Cancer Research Center 2015-06-17
NCT00970385 Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma https://ClinicalTrials.gov/show/NCT00970385 Completed University Hospital, Grenoble 2002-12-31
NCT00963274 Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma https://ClinicalTrials.gov/show/NCT00963274 Completed Virginia Commonwealth University 2014-07-17
NCT00961220 O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00961220 Completed National Cancer Institute (NCI) 2012-04-08
NCT00959686 Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma https://ClinicalTrials.gov/show/NCT00959686 Completed French Innovative Leukemia Organisation 2011-06-30
NCT00930605 The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL) https://ClinicalTrials.gov/show/NCT00930605 Completed King Chulalongkorn Memorial Hospital 2006-11-30
NCT00918333 Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00918333 Completed Mayo Clinic 2015-12-01
NCT00901147 Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma https://ClinicalTrials.gov/show/NCT00901147 Completed Singapore General Hospital 2014-01-31
NCT00896493 Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma https://ClinicalTrials.gov/show/NCT00896493 Active, not recruiting Stanford University 2022-12-31
NCT00891072 Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery https://ClinicalTrials.gov/show/NCT00891072 Completed National Cancer Institute (NCI) 2011-04-30
NCT00890747 Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy https://ClinicalTrials.gov/show/NCT00890747 Completed National Cancer Institute (NCI) 2011-05-31
NCT00888927 Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT00888927 Completed Kyowa Kirin Pharmaceutical Development, Inc. 2012-09-30
NCT00880815 Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00880815 Completed M.D. Anderson Cancer Center 2019-05-28
NCT00877656 HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00877656 Completed Emergent BioSolutions 2006-01-31
NCT00865969 Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00865969 Completed Spectrum Pharmaceuticals, Inc 2014-10-31
NCT00856388 Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders https://ClinicalTrials.gov/show/NCT00856388 Completed Roswell Park Cancer Institute 2012-08-09
NCT00854425 L-asparaginase Monotherapy as Salvage Treatment in Patients With NK/T Cell Lymphoma https://ClinicalTrials.gov/show/NCT00854425 Completed Fudan University 2012-01-31
NCT04319601 Rituximab Combined With Chidamide and Lenalidomide for r/r AITL https://ClinicalTrials.gov/show/NCT04319601 Recruiting Zhejiang Cancer Hospital 2022-03-31
NCT03595657 A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma https://ClinicalTrials.gov/show/NCT03595657 Recruiting CStone Pharmaceuticals 2020-12-31
NCT02544425 VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT) https://ClinicalTrials.gov/show/NCT02544425 Recruiting Samsung Medical Center 2019-11-30
NCT00807495 Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00807495 Completed Takeda 2011-01-04
NCT01658319 Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01658319 Completed Case Comprehensive Cancer Center 2015-02-28
NCT01553786 Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL) https://ClinicalTrials.gov/show/NCT01553786 Completed The Lymphoma Academic Research Organisation 2018-03-31
NCT02953301 Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) https://ClinicalTrials.gov/show/NCT02953301 Recruiting 4SC AG 2022-01-31
NCT03061188 Nivolumab and Veliparib in Treating Patients With Recurrent or Refractory Stage IV Solid Tumors That Cannot Be Removed by Surgery or Lymphoma With or Without Alterations in DNA Repair Genes https://ClinicalTrials.gov/show/NCT03061188 Active, not recruiting Northwestern University 2020-09-30
NCT02580552 Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL https://ClinicalTrials.gov/show/NCT02580552 Active, not recruiting miRagen Therapeutics, Inc. 2020-12-31
NCT02733458 GELAD Chemotherapy and Sandwiched Radiotherapy in the Treatment of Stage IE/IIE Natural Killer/T-cell Lymphoma https://ClinicalTrials.gov/show/NCT02733458 Recruiting Xinhua Hospital, Shanghai Jiao Tong University School of Medicine 2020-12-31
NCT02341014 Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas https://ClinicalTrials.gov/show/NCT02341014 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-01-31
NCT01701986 Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01701986 Recruiting M.D. Anderson Cancer Center 2020-05-01
NCT03776279 A Study of Liposome-entrapped Mitoxantrone Hydrochloride Injection in Relapsed/Refractory Peripheral T-cell Lymphoma and NK/T-cell Lymphoma https://ClinicalTrials.gov/show/NCT03776279 Recruiting CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 2020-12-30
NCT00791947 A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT https://ClinicalTrials.gov/show/NCT00791947 Completed University of Aarhus 2008-08-31
NCT00787527 SAHA + CHOP in Untreated T-cell Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00787527 Completed M.D. Anderson Cancer Center 2012-12-31
NCT00771472 Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1) https://ClinicalTrials.gov/show/NCT00771472 Completed Merck Sharp & Dohme Corp. 2011-07-31
NCT00769288 FAU in Treating Patients With Advanced Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT00769288 Completed National Cancer Institute (NCI) 2013-12-31
NCT00748319 Killer Immunoglobulin-Like Receptor Transcripts Expression for the Diagnosis of Epidermotropic Cutaneous T Cell Lymphoma https://ClinicalTrials.gov/show/NCT00748319 Completed Assistance Publique - Hôpitaux de Paris 2011-11-30
NCT00744991 A Study for Patients With Relapsed Cutaneous T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00744991 Completed Eli Lilly and Company 2010-01-31
NCT00723099 Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer https://ClinicalTrials.gov/show/NCT00723099 Completed Fred Hutchinson Cancer Research Center 2018-07-31
NCT00697346 Study of MLN8237 in Participants With Advanced Hematological Malignancies https://ClinicalTrials.gov/show/NCT00697346 Completed Takeda 2016-10-01
NCT00684411 Gleevec in Relapsed/Refractory T Cell Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00684411 Completed Dana-Farber Cancer Institute 2013-10-31
NCT00660231 Gemcitabine and Bexarotene in Treating Patients With Progressive or Refractory Stage IB, Stage II, Stage III, or Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00660231 Completed University College, London 2011-09-30
NCT00646854 Alemtuzumab and CHOP in T-cell Lymphoma https://ClinicalTrials.gov/show/NCT00646854 Completed University of Aarhus 2016-12-31
NCT00644189 Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00644189 Active, not recruiting Massachusetts General Hospital 2013-12-31
NCT00611208 A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) https://ClinicalTrials.gov/show/NCT00611208 Completed Angimmune LLC 2015-02-28
NCT00608361 Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery https://ClinicalTrials.gov/show/NCT00608361 Completed National Cancer Institute (NCI) 2014-08-31
NCT00601718 Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00601718 Completed University of Washington 2010-06-30
NCT00554827 Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma https://ClinicalTrials.gov/show/NCT00554827 Completed Acrotech Biopharma LLC 2012-01-31
NCT00536601 High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors https://ClinicalTrials.gov/show/NCT00536601 Completed Roswell Park Cancer Institute 2018-07-09
NCT00506129 Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00506129 Completed M.D. Anderson Cancer Center 2015-06-30
NCT00501735 Forodesine in the Treatment of Cutaneous T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00501735 Completed BioCryst Pharmaceuticals 2010-07-31
NCT00499811 Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction https://ClinicalTrials.gov/show/NCT00499811 Completed National Cancer Institute (NCI) 2011-08-31
NCT00490776 Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00490776 Completed Novartis 2009-09-30
NCT00489203 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00489203 Completed Fred Hutchinson Cancer Research Center 2010-11-30
NCT00481871 Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies https://ClinicalTrials.gov/show/NCT00481871 Completed Acrotech Biopharma LLC 2011-05-31
NCT00458731 Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma https://ClinicalTrials.gov/show/NCT00458731 Completed National Cancer Institute (NCI) 2013-12-31
NCT00453427 Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas https://ClinicalTrials.gov/show/NCT00453427 Completed Ontario Clinical Oncology Group (OCOG) 2013-06-30
NCT00438802 Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00438802 Completed Mayo Clinic 2010-08-24
NCT00431912 A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma https://ClinicalTrials.gov/show/NCT00431912 Completed Onxeo 2011-01-31
NCT00426764 A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT00426764 Completed Celgene 2010-11-11
NCT00425555 Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00425555 Completed Novartis 2013-06-30
NCT00418535 Clinical Study of Chemoradiation Followed by VIPD in Nasal Natural Killer (NK)/T-cell Lymphoma https://ClinicalTrials.gov/show/NCT00418535 Completed Samsung Medical Center 2009-03-31
NCT00412997 LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma https://ClinicalTrials.gov/show/NCT00412997 Completed Novartis 2008-05-31
NCT00408681 Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00408681 Completed Fred Hutchinson Cancer Research Center 2010-11-30
NCT00406809 A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT00406809 Completed AbbVie 2016-10-31
NCT00799461 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications https://ClinicalTrials.gov/show/NCT00799461 Completed Fred Hutchinson Cancer Research Center 2011-11-30
NCT00374699 Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas https://ClinicalTrials.gov/show/NCT00374699 Completed Samsung Medical Center 2009-09-30
NCT00364923 Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT00364923 Completed Acrotech Biopharma LLC 2009-01-31
NCT00355472 Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL https://ClinicalTrials.gov/show/NCT00355472 Completed Kyowa Kirin Co., Ltd. 2008-10-31
NCT00348985 PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas https://ClinicalTrials.gov/show/NCT00348985 Completed National Cancer Institute (NCI) 2010-01-31
NCT00343798 A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00343798 Completed Fred Hutchinson Cancer Research Center 2013-07-31
NCT00337987 A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00337987 Completed Yale University 2007-12-31
NCT00336063 Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00336063 Active, not recruiting National Cancer Institute (NCI) 2013-04-19
NCT00322985 A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00322985 Completed AHS Cancer Control Alberta 2014-05-31
NCT00306969 Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00306969 Completed Boston University NA
NCT00293345 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT00293345 Completed National Cancer Institute (NCI) 2012-10-31
NCT00292695 A Phase II Study of Nasal NK/T-cell Lymphoma https://ClinicalTrials.gov/show/NCT00292695 Completed National Health Research Institutes, Taiwan 2009-12-31
NCT00290433 Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00290433 Completed M.D. Anderson Cancer Center 2015-07-31
NCT00283985 Association of L-asparaginase-Methotrexate-Dexamethasone for Nasal and Nasal-type Natural Killer (NK)-T-cell Lymphoma https://ClinicalTrials.gov/show/NCT00283985 Completed University Hospital, Limoges 2012-06-30
NCT00255801 Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00255801 Completed Memorial Sloan Kettering Cancer Center 2017-10-31
NCT00221039 Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A https://ClinicalTrials.gov/show/NCT00221039 Completed M.D. Anderson Cancer Center 2011-04-05
NCT00211198 Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) https://ClinicalTrials.gov/show/NCT00211198 Completed Eisai Inc. 2005-01-31
NCT00211185 A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00211185 Completed Eisai Inc. 2008-08-31
NCT00182637 Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00182637 Completed Jonsson Comprehensive Cancer Center 2010-09-30
NCT00178841 Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL https://ClinicalTrials.gov/show/NCT00178841 Completed Vanderbilt University 2007-03-31
NCT00136565 Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT00136565 Completed Lymphoma Study Association 2011-04-18
NCT00131937 Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00131937 Completed National Cancer Institute (NCI) 2011-09-30
NCT00118352 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00118352 Completed Fred Hutchinson Cancer Research Center 2010-07-31
NCT00112593 Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer https://ClinicalTrials.gov/show/NCT00112593 Completed Fred Hutchinson Cancer Research Center 2014-11-30
NCT00109928 S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00109928 Completed Southwest Oncology Group 2012-06-30
NCT00106431 A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL) https://ClinicalTrials.gov/show/NCT00106431 Completed Celgene 2008-06-01
NCT00099593 Immunization Against Tumor Cells in Sezary Syndrome https://ClinicalTrials.gov/show/NCT00099593 Completed FDA Office of Orphan Products Development NA
NCT00098891 MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas https://ClinicalTrials.gov/show/NCT00098891 Completed National Cancer Institute (NCI) 2008-03-31
NCT00098332 Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00098332 Completed National Cancer Institute (NCI) 2010-12-31
NCT00091559 Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001) https://ClinicalTrials.gov/show/NCT00091559 Completed Merck Sharp & Dohme Corp. 2005-11-23
NCT00002635 Aminocamptothecin in Treating Patients With T-cell Lymphoma https://ClinicalTrials.gov/show/NCT00002635 Completed Yale University 2000-04-30
NCT00089271 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas https://ClinicalTrials.gov/show/NCT00089271 Completed National Cancer Institute (NCI) 2010-06-30
NCT00089011 Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00089011 Completed Fred Hutchinson Cancer Research Center 2014-03-31
NCT00003196 Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma https://ClinicalTrials.gov/show/NCT00003196 Completed Fred Hutchinson Cancer Research Center 2002-04-30
NCT00798096 Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00798096 Completed Rigel Pharmaceuticals 2010-04-30
NCT00006251 Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer https://ClinicalTrials.gov/show/NCT00006251 Completed Fred Hutchinson Cancer Research Center 2005-09-30
NCT00082888 Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma https://ClinicalTrials.gov/show/NCT00082888 Completed National Cancer Institute (NCI) 2009-05-20
NCT00005080 506U78 in Treating Patients With Lymphoma https://ClinicalTrials.gov/show/NCT00005080 Completed National Cancer Institute (NCI) 2006-01-31
NCT00080535 Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas https://ClinicalTrials.gov/show/NCT00080535 Completed National Institutes of Health Clinical Center (CC) 2011-12-31
NCT00005799 Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer https://ClinicalTrials.gov/show/NCT00005799 Completed Fred Hutchinson Cancer Research Center 2002-07-31
NCT00006345 Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00006345 Completed National Cancer Institute (NCI) NA
NCT00078858 Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00078858 Completed Fred Hutchinson Cancer Research Center 2006-01-31
NCT00077155 Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT00077155 Completed National Cancer Institute (NCI) 2010-06-30
NCT00072514 Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT00072514 Completed Fred Hutchinson Cancer Research Center 2008-07-31
NCT00071084 Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin. https://ClinicalTrials.gov/show/NCT00071084 Completed Emergent Product Development Seattle LLC 2004-06-30
NCT00071071 Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin. https://ClinicalTrials.gov/show/NCT00071071 Completed Emergent Product Development Seattle LLC 2004-05-31
NCT00069238 Campath-1H and EPOCH to Treat Non-Hodgkin’s T- and NK-Cell Lymphomas https://ClinicalTrials.gov/show/NCT00069238 Active, not recruiting National Institutes of Health Clinical Center (CC) 2009-06-11
NCT00003210 Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin’s Lymphoma or Hodgkin’s Disease https://ClinicalTrials.gov/show/NCT00003210 Completed National Cancer Institute (NCI) 2003-11-30
NCT00061880 BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00061880 Completed National Cancer Institute (NCI) 2005-01-31
NCT00049504 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer https://ClinicalTrials.gov/show/NCT00049504 Completed Fred Hutchinson Cancer Research Center 2011-03-31
NCT00040846 Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT00040846 Completed Fred Hutchinson Cancer Research Center 2009-12-31
NCT00030849 Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00030849 Completed National Cancer Institute (NCI) 2004-09-30
NCT00795769 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00795769 Completed Fred Hutchinson Cancer Research Center 2009-06-09
NCT00020072 Analysis of Genes Present in Cutaneous T-cell Lymphoma Cells https://ClinicalTrials.gov/show/NCT00020072 Completed National Cancer Institute (NCI) NA
NCT00014235 Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00014235 Completed Fred Hutchinson Cancer Research Center 2005-02-28
NCT00004241 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma https://ClinicalTrials.gov/show/NCT00004241 Completed National Cancer Institute (NCI) 2006-05-31
NCT00051597 A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00051597 Completed Seattle Genetics, Inc. NA
NCT00051012 Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients https://ClinicalTrials.gov/show/NCT00051012 Completed Eisai Inc. 2006-10-31
NCT00050999 Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients https://ClinicalTrials.gov/show/NCT00050999 Completed Eisai Inc. 2006-09-30
NCT00001249 Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac https://ClinicalTrials.gov/show/NCT00001249 Completed National Institutes of Health Clinical Center (CC) NA
NCT00043420 CPG 7909 in Patients With Cutaneous T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00043420 Completed Pfizer 2007-03-31
NCT00043368 PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909) https://ClinicalTrials.gov/show/NCT00043368 Completed Pfizer 2007-06-30
NCT00038376 Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies https://ClinicalTrials.gov/show/NCT00038376 Completed M.D. Anderson Cancer Center 2005-06-30
NCT00038025 A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT00038025 Completed M.D. Anderson Cancer Center 2006-11-29
NCT00003970 Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT00003970 Completed National Cancer Institute (NCI) 2003-10-31
NCT00025415 Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction https://ClinicalTrials.gov/show/NCT00025415 Completed National Cancer Institute (NCI) 2005-01-31
NCT00007345 Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00007345 Completed National Institutes of Health Clinical Center (CC) 2015-01-26

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03297697 Minimal Residual Disease in Peripheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT03297697 Active, not recruiting Washington University School of Medicine 2021-07-31
NCT03079544 Social Media-based Active Self-report on Incidence and Outcomes of Adverse Events in NK/TCL Patients https://ClinicalTrials.gov/show/NCT03079544 Recruiting Xinhua Hospital, Shanghai Jiao Tong University School of Medicine 2022-12-30
NCT03040206 Risk Stratification of Nodal PTCL https://ClinicalTrials.gov/show/NCT03040206 Completed Chonbuk National University Hospital 2017-06-30
NCT02840747 Tissue Repository: CTCL Collection Protocol https://ClinicalTrials.gov/show/NCT02840747 Recruiting Columbia University 2021-01-31
NCT02788916 A Retrospective Study of Clinical, Phenotypic and Genetic Factors of Peripheral T-Cell Lymphomas https://ClinicalTrials.gov/show/NCT02788916 Completed Takeda 2016-11-10
NCT02520908 Benefit of Allogeneic Haematopoietic Stem Cells in Cutaneous T-cell Lymphomas Epidermotropic With Advanced Stage and Poor Prognosis https://ClinicalTrials.gov/show/NCT02520908 Recruiting Assistance Publique - Hôpitaux de Paris 2021-09-30
NCT02386813 International Extranodal NK/T-cell Lymphoma Project https://ClinicalTrials.gov/show/NCT02386813 Completed Samsung Medical Center 2015-06-30
NCT03356678 Pralatrexate for Relapsed or Refractory Peripheral T-cell Lymphoma https://ClinicalTrials.gov/show/NCT03356678 Completed Samsung Medical Center 2017-06-30
NCT01941680 High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant https://ClinicalTrials.gov/show/NCT01941680 Active, not recruiting University Hospital Center of Martinique 2018-02-28
NCT01660568 Gemcitabine in NK/T Cell Lymphoma https://ClinicalTrials.gov/show/NCT01660568 Completed Samsung Medical Center 2013-01-31
NCT01460914 Outcomes of Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease With Extracorporeal Photopheresis Treatment https://ClinicalTrials.gov/show/NCT01460914 Active, not recruiting Dartmouth-Hitchcock Medical Center 2050-09-30
NCT01341119 Retrospective Analysis of Skin/Soft Tissue Primary NK/T Cell Lymphoma https://ClinicalTrials.gov/show/NCT01341119 Completed Samsung Medical Center NA
NCT04423536 Predictive Value of a SNP Signature and Liquid Biopsy in Natural Killer T-cell Lymphoma https://ClinicalTrials.gov/show/NCT04423536 Recruiting Sun Yat-sen University 2021-06-30
NCT04213209 Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion “Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma” https://ClinicalTrials.gov/show/NCT04213209 Recruiting Takeda 2022-12-31
NCT03932279 Characterization of the Microbiome in Cutaneous T Cell Lymphoma https://ClinicalTrials.gov/show/NCT03932279 Recruiting Northwestern University 2020-12-31
NCT03789864 Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis Fungoides https://ClinicalTrials.gov/show/NCT03789864 Recruiting Indiana University 2021-05-01
NCT03742921 ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT03742921 Recruiting Celgene 2023-04-17
NCT03672084 Allo-HSCT as First-line Consolidation in High-risk PTCL https://ClinicalTrials.gov/show/NCT03672084 Recruiting Peking University People’s Hospital 2021-08-31
NCT01199562 Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01199562 Completed City of Hope Medical Center 2013-12-31
NCT01142674 T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01142674 Completed Associazione Angela Serra per la ricerca sul cancro 2016-07-31
NCT01110733 Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry https://ClinicalTrials.gov/show/NCT01110733 Completed Acrotech Biopharma LLC 2019-12-31
NCT01000753 Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01000753 Active, not recruiting Children’s Oncology Group 2007-06-01
NCT02836886 VircapSeq Virus Detection in Sézary Syndrome https://ClinicalTrials.gov/show/NCT02836886 Completed Columbia University 2016-10-31
NCT01087333 Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment https://ClinicalTrials.gov/show/NCT01087333 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT00731536 Observational Study on the Occurrence of Hepatosplenic T-cell Lymphoma in Patients of Netherlands https://ClinicalTrials.gov/show/NCT00731536 Completed Centocor Ortho Biotech Services, L.L.C. 2010-04-30
NCT00705809 T-Cell Project: Epidemiologic Component https://ClinicalTrials.gov/show/NCT00705809 Completed National Institutes of Health Clinical Center (CC) NA
NCT00430053 Clinical Evaluations and Laboratory Studies to Study the Disease Course in Patients With Cutaneous T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00430053 Completed National Institutes of Health Clinical Center (CC) NA
NCT00254332 Effect of Denileukin Diftitox on Immune System in CTCL Patients https://ClinicalTrials.gov/show/NCT00254332 Completed FDA Office of Orphan Products Development NA
NCT00177268 Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research https://ClinicalTrials.gov/show/NCT00177268 Recruiting University of Pittsburgh 2027-01-31
NCT00177190 In Vitro Evaluation of Immune Responses in Cutaneous T-Cell Lymphoma (CTCL) https://ClinicalTrials.gov/show/NCT00177190 Completed University of Pittsburgh 2005-01-31

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT03207789 T-cell Brazil: Prospective Collection of Data in T-cell Lymphomas Patients https://ClinicalTrials.gov/show/NCT03207789 Enrolling by invitation Grupo de Estudos Multicentricos em Onco-Hematologia 2017-06-01
NCT02691351 Intercontinental Cooperative Non-Hodgkin T-cell Lymphoma Prospective Registry Study https://ClinicalTrials.gov/show/NCT02691351 Active, not recruiting Samsung Medical Center 2020-12-31
NCT02296164 Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma https://ClinicalTrials.gov/show/NCT02296164 Completed Helsinn Therapeutics (U.S.), Inc 2018-10-17
NCT03964480 Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma. https://ClinicalTrials.gov/show/NCT03964480 Recruiting Associazione Angela Serra per la ricerca sul cancro 2023-01-30
NCT03646422 AEDV Registry of Primary Cutaneous Lymphoma https://ClinicalTrials.gov/show/NCT03646422 Recruiting Fundación Academia Española de Dermatología 2025-01-01